Elixinol Wellness Ltd · ASX:EXL
Elixinol Wellness — Elixinol Global — 1H FY2018 Earnings Presentation
22 slides from Elixinol Wellness's earnings presentation, Aug 29, 2018
Slide 1: Elixinol Global Limited 1H FY2018 Results Presentation
For personal use only DRAFT Elixinol Global Limited 1H FY2018 Results Presentation ASX: EXL | www.elixinolglobal.com
Slide 2: Disclaimer
Disclaimer This presentation contains summary information about Elixinol Group Limited (Elixinol) and its subsidiaries and their activities. The information in this For personal use only presentation does not purport to be complete. It should be read in conjunction with Elixinol’s other periodic and
Slide 3: Agenda
Summary Agenda For personal use only Key highlights for 1H FY2018 4 Business overview 6 Financial results 15 Q&A 19 Appendix 20 Page 3 Company Presentation February 2018
Slide 4: Key highlights for 1H FY2018
For personal use only Key highlights forDRAFT 1H FY2018
Slide 5: Key highlights for 1H FY2018
Key highlights for 1H FY2018 1 Revenue 1H FY2018 $14.9m vs 1H FY2017 $7.1m, 110% growth H1 FY18 – EXL isUnderlying positioned for strong, EBITDA continued growth 1H FY2018 $0.8m vs 1H FY2017 ($0.1)m loss For personal use only Group results 1H FY2018 Underlying NPAT 1H FY2018 $0.6m vs 1H FY2017 ($0.3
Slide 6: Business overview
For personal use only Business overviewDRAFT Page 6
Slide 7: Diversified portfolio
Diversified portfolio 1H FY2018 revenue by business unit For personal use only Consumer Products Pharmaceutical Dietary Supplements Hemp Foods Medicinal Cannabis Revenue $12.54m (84%) Revenue $2.34m (16%) Seeking licence and permit Submitted licence applications for cultivation and manufacture to Of
Slide 8: Strong growth trajectory across key metrics
Strong growth trajectory across key metrics EXL has maintained a strong growth trajectory and delivered a maiden profit in 1H FY2018 For personal use only Revenue Underlying EBITDA ($m) A$ million, 31 December year end 1H A$ million, 31 December year end 1H 16.5 2H 2H 9.4 0.8 14.9 110% 7.1 0.02 0.10
Slide 9: Revenue growth by Consumer Products segment
Revenue growth by Consumer Products segment Growth across all revenue segments with a clear strategy to drive higher margin products For personal use only Elixinol USA Hemp Foods Australia A$ million, 31 December year end 1H FY2017 A$ million, 31 December year end 1H FY2017 1H FY2018 1H FY2018 5.0 2
Slide 10: Elixinol Global 1H FY2018 growth initiatives
Elixinol Global 1H FY2018 growth initiatives Disciplined approach to drive future growth For personal use only • Investment in farming and production capabilities to facilitate future growth • Key sales hires focused on retail distribution which is higher margin • Continued focus on core products an
Slide 11: Elixinol Global international footprint
Elixinol Global international footprint An established platform that can be leveraged for consumer products For personal use only Global platform for growth • Avenues to market established in 40 countries with mix of direct sales and via distribution partners • Facilities (pins) in: • Sydney and Ban
Slide 12: Elixinol USA: positioned for future growth
Elixinol USA: positioned for future growth Increased capacity and product development to drive earnings and margin improvement For personal use only • Elixinol USA is relocating to a new facility in Colorado, USA, designed to be GMP certified and will more than double the usable capacity for process
Slide 13: Hemp Foods Australia: industry leader
Hemp Foods Australia: industry leader Focus on growth of core products and new product offerings For personal use only • Core product range includes hemp oils, flours, seeds, protein • currently sold via e-commerce and health food shops • Hemp Foods Australia supplying to major FMCG brands including
Slide 14: Elixinol Australia (medicinal cannabis)
Elixinol Australia (medicinal cannabis) Advanced development plans are prepared For personal use only • Strategy to enter Australian medicinal cannabis market and develop export capability • Submitted licence applications for cultivation and manufacture to the Office of Drug Control (ODC) in Awaitin
Slide 15: 1H FY2018 financial results
For personal use only 1H FY2018 financial results DRAFT Page 15
Slide 16: Financial summary
Financial summary Growth across all revenue segments to achieve maiden profit For personal use only 1H 1H Commentary ($m) FY2018 FY2017 Revenue • growth across all revenue segments has enabled Elixinol Group Revenue 14.9 7.1 revenues to increase 110% vs PCP Cost of goods sold (6.5) (2.6) • dietary s
Slide 17: Cash flow
Cash flow Re-investment to facilitate expected future growth For personal use only 1H 1H Commentary ($m) FY2018 FY2017 Operating cash flow • working capital expenditure to facilitate expected future Operating activities (1.3) (1.2) growth • deposits to secure raw material for FY2019 harvest • income
Slide 18: Strong financial position
Strong financial position Strong cash position and minimal debt For personal use only 30 June 31 Dec Commentary ($m) 2018 2017 Current assets Strong cash position Cash and cash equivalents 14.2 18.8 • strong cash position of $14.2m Trade & other receivables 1.8 1.2 • increase in inventories to suppo
Slide 19: Q&A
For personal use only Page 19 Q&A DRAFT
Slide 20: Appendix
For personal use only Page 20 Appendix DRAFT
Slide 21: Reconciliation to 1H FY2018 underlying EBITDA and NPAT
Reconciliation to 1H FY2018 underlying EBITDA and NPAT For personal use only ($m) 1H FY2018 Statutory NPAT 0.1 Tax expense 0.2 Depreciation & amortisation 0.4 Interest income/finance costs (0.2) Statutory EBITDA 0.6 Share based payment expense 0.2 Underlying EBITDA 0.8 Statutory NPAT 0.1 Share based
Slide 22: For more information
For personal use only For more information: Paul Benhaim Ron Dufficy Chief Executive Officer Chief Financial Officer DRAFT paul@elixinolglobal.com ron.dufficy@elixinolglobal.com +61 407 767 709 +61 428 881 718